Correlation between GABA(A) receptor density and vagus nerve stimulation in individuals with drug-resistant partial epilepsy
- PMID: 12948617
- DOI: 10.1016/s0920-1211(03)00107-4
Correlation between GABA(A) receptor density and vagus nerve stimulation in individuals with drug-resistant partial epilepsy
Abstract
Vagus nerve stimulation (VNS) is an important option for the treatment of drug-resistant epilepsy. Through delivery of a battery-supplied intermittent current, VNS protects against seizure development in a manner that correlates experimentally with electrophysiological modifications. However, the mechanism by which VNS inhibits seizures in humans remains unclear. The impairment of gamma-aminobutyric acid (GABA)-mediated neuronal inhibition associated with epilepsy has suggested that GABA(A) receptors might contribute to the therapeutic efficacy of VNS. We have now applied single photon emission computed tomography (SPECT) with the benzodiazepine receptor inverse agonist [123I]iomazenil to examine cortical GABA(A) receptor density (GRD) before and 1 year after implantation of a VNS device in 10 subjects with drug-resistant partial epilepsy. VNS therapeutic responses resulted significantly correlated with the normalization of GRD. Moreover, a comparable control group, scheduled for a possible VNS implant, failed to show significant GRD variations after 1 year of a stable anti-epileptic treatment. These results suggest that VNS may modulate the cortical excitability of brain areas associated with epileptogenesis and that GABA(A) receptor plasticity contributes to this effect.
Similar articles
-
Vagus nerve stimulation for treatment of partial seizures: 1. A controlled study of effect on seizures. First International Vagus Nerve Stimulation Study Group.Epilepsia. 1994 May-Jun;35(3):616-26. doi: 10.1111/j.1528-1157.1994.tb02482.x. Epilepsia. 1994. PMID: 8026408 Clinical Trial.
-
Vagus nerve stimulation for treatment of partial seizures: 2. Safety, side effects, and tolerability. First International Vagus Nerve Stimulation Study Group.Epilepsia. 1994 May-Jun;35(3):627-36. doi: 10.1111/j.1528-1157.1994.tb02483.x. Epilepsia. 1994. PMID: 8026409 Clinical Trial.
-
Vagus nerve stimulation use and effect in epilepsy: what have we learned?Epilepsy Behav. 2006 Feb;8(1):127-36. doi: 10.1016/j.yebeh.2005.09.006. Epub 2005 Dec 20. Epilepsy Behav. 2006. PMID: 16376157 Review.
-
[Vagus nerve stimulation and refractory partial epilepsies].Rev Neurol (Paris). 2004 Jun;160 Spec No 1:5S280-7. Rev Neurol (Paris). 2004. PMID: 15331976 Review. French.
-
Brain blood flow alterations induced by therapeutic vagus nerve stimulation in partial epilepsy: I. Acute effects at high and low levels of stimulation.Epilepsia. 1998 Sep;39(9):983-90. doi: 10.1111/j.1528-1157.1998.tb01448.x. Epilepsia. 1998. PMID: 9738678
Cited by
-
Evaluating the Efficacy of Vagus Nerve Stimulation across 'Minor' and 'Major' Seizure Types: A Retrospective Analysis of Clinical Outcomes in Pharmacoresistant Epilepsy.J Clin Med. 2024 Jul 14;13(14):4114. doi: 10.3390/jcm13144114. J Clin Med. 2024. PMID: 39064154 Free PMC article.
-
Advances in the treatment of depression.NeuroRx. 2006 Jan;3(1):42-56. doi: 10.1016/j.nurx.2005.12.007. NeuroRx. 2006. PMID: 16490412 Free PMC article. Review.
-
Mechanism and Applications of Vagus Nerve Stimulation.Curr Issues Mol Biol. 2025 Feb 14;47(2):122. doi: 10.3390/cimb47020122. Curr Issues Mol Biol. 2025. PMID: 39996843 Free PMC article. Review.
-
Implications of microbe-derived ɣ-aminobutyric acid (GABA) in gut and brain barrier integrity and GABAergic signaling in Alzheimer's disease.Gut Microbes. 2024 Jan-Dec;16(1):2371950. doi: 10.1080/19490976.2024.2371950. Epub 2024 Jul 15. Gut Microbes. 2024. PMID: 39008552 Free PMC article. Review.
-
Age-related phenotype and biomarker changes in SSADH deficiency.Ann Clin Transl Neurol. 2018 Dec 3;6(1):114-120. doi: 10.1002/acn3.696. eCollection 2019 Jan. Ann Clin Transl Neurol. 2018. PMID: 30656189 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources